9,10 Along with the aforementioned currently approved and evidence-based FDA indications, other disorders that may possibly receive FDA approval include heart failure with preserved ejection fraction, peripheral artery disease, arthritis, and polyendocrine metabolic ovarian syndrome (PMOS)
(Primary completion November 2025, 68-week treatment period, 4mg/9mg/12mg dose arms
Other FDA-approved GLP-1 receptor agonists, including liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and semaglutide (Ozempic, Wegovy, Rybelsus), are not directly derived from lizard venom
July 9, 2025
Concentration = Peptide Amount (mg) / Water Volume (mL) That is the entire foundation
If you prescribe antipsychotics, mood stabilizers, or certain antidepressants, youre already managing weight as a clinical issue